Product · #9 of 27 · perimenopause
Amberen Perimenopause
Capsule (white + purple) from Amberen, made by Alliance Pharmaceuticals. Daily serving: 2 capsules.
Last updated · Price and ratings checked Nov 19, 2026
In short: Amberen Perimenopause scores 51.7/100 in our ranking (#9 of 27). It costs $1.00 a day at the regular price. Evidence: succinate blend; open-label trial only; best ingredient grade C (Ammonium succinate (Amberen)). No NSF registry listing was confirmed.
Pros
- Widely reviewed: ★ 4.3 from 1,308 Amazon ratings.
Cons
- No NSF registry listing confirmed.
- Proprietary blend: some ingredient amounts are not disclosed.
- Legal or regulatory history: see flags below.
Flags
FTC orderFTC noticeWatchdog complaintUndisclosed amounts
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Vitamin E | 5.04 mg | Not in our evidence library |
| Vitamin B6 | 2 mg | Not in our evidence library |
| Vitamin B12 | 2 mcg | Not in our evidence library |
| Amberen perimenopause proprietary compound: ammonium succinate, disodium fumarate, calcium disuccinate, monosodium L-glutamate, glycine, magnesium disuccinate, zinc difumarateamount not captured/undisclosed | amount not disclosed | Ammonium succinate (Amberen) C |
Dose panel from a retailer (H-E-B) listing, not an official label. Unverified
Evidence
Our evidence score: 22/40, because: succinate blend; open-label trial only.
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- Ammonium succinate (Amberen) C (amount not disclosed here)
Amberen's ammonium-succinate blend has been studied for common menopause symptoms* in two placebo-controlled trials and one open-label study, all linked to the manufacturer. The amount of each component is not disclosed. The Menopause Society 2023: Not recommended (Level II) – limited, manufacturer-sponsored.
Studies
Studies on its ingredients (4)
-
Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial.
125 Russian women took Amberen or placebo for 3 months. Many symptom scores and anxiety improved more on Amberen. NAMS notes this research was paid for by the manufacturer.
- Who
- 125 women aged 42–60
- Dose
- Amberen (ammonium succinate-based)
- Duration
- 3 months
- Result
- Improvement in 13 of 21 Greene symptoms vs placebo; reduced anxiety; estradiol/leptin changes, weight loss.
- Funding
- Not stated in abstract; manufacturer-sponsored per NAMS 2023. Industry-linked
-
Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
Two identical 90-day Russian trials (227 women) were pooled; Amberen beat placebo on many menopause symptoms. Both trials are manufacturer-linked and have not been repeated independently.
- Who
- 227 women (pooled 2 identical RCTs)
- Dose
- Amberen
- Duration
- 90 days
- Result
- 16 of 21 Greene symptoms improved vs placebo; anxiety down; weight and waist reduced; estradiol rose.
- Funding
- Manufacturer-linked: an author is a paid consultant to Biogix (formerly Lunada Biomedical, Amberen's maker). Industry-linked
-
Multivessel Spontaneous Coronary Artery Dissection: Amberen as a Possible Risk Factor.
A single case report described a rare heart-artery tear in a woman taking Amberen. One case cannot prove cause, but it is worth knowing.
- Who
- 1 case
- Dose
- Amberen
- Duration
- n/a
- Result
- Case of multivessel spontaneous coronary artery dissection possibly linked to Amberen.
- Funding
- Case report. Independent / academic
-
Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen(®) and Smart B(®) in Women with Climacteric Syndrome in Perimenopause.
106 women took Amberen with a companion product, with no placebo group. Symptoms improved over the study, but without a comparison group this cannot show the product caused the change.
- Who
- 106 perimenopausal women (open-label, no placebo)
- Dose
- Amberen + Smart B
- Duration
- per paper
- Result
- Greene, anxiety, depression and well-being scores improved from baseline.
- Funding
- Not stated in abstract (product study). Funding not stated
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $29.99 (60 units, 30 days at label dose) |
|---|---|
| Cost per day | $1.00 |
| Subscription | None listed |
| Price notes | Regular $29.99 shown on amberen.com product page (but 'can no longer purchase directly'); Amazon B0C3T4CHQ2 $21.81 |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.3 from 1,308 ratings on Amazon (checked Nov 19, 2026)
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “clinically proven (own 90-day perimenopause trial)” Brand claim
Registry check: NSF/ANSI 173: not found
Who's behind it
| Brand | Amberen |
|---|---|
| Owner / company | Alliance Pharmaceuticals Ltd (UK; US entity Alliance Pharma Inc). Originally Lunada Biomedical. |
| Founders | Not stated on the pages we read. |
| Where it's made | not stated. |
| Medical advisors named | None named on the pages we read. |
| Source | amberen.com · alliancepharmaceuticals.com |
Flags & safety
Legal, regulatory and quality flags
- FTC v. Lunada Biomedical (2015–2016): stipulated order bars unsubstantiated weight-loss and menopause-relief claims; $40M judgment suspended on $250k payment. ftc.gov
- TINA.org complaint to FTC/FDA (Oct 2024) alleging Amberen marketing violates the 2016 order; FTC Notice of Penalty Offenses sent to Alliance (Apr 2023). truthinadvertising.org
- Proprietary blend: individual succinate amounts not disclosed.
Ingredient safety notes
- Ammonium succinate (Amberen): One case report of spontaneous coronary artery dissection (causality unproven). Trials reported estradiol increase.
Not verified
- Doses (from a retailer listing, not the official label). Unverified
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.